Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


OTCPK:ATBPF - Post by User

Comment by MrMugsyon Jun 18, 2021 8:25am
240 Views
Post# 33410098

RE:RE:RE:What you see now

RE:RE:RE:What you see now
woundedknee wrote: When emotions take over mistakes will be made. and aftera good night's sleep; can't let that happen. And bagger, I'm not the ceo of this company. There is a time, place and circumstance for insiders to sell. Even an NR explaining the insider sale might help allay fears that something has gone astray.  jmo We are still falling and it's a long summer. So I have to look at it like we are at 36 cents (pre split) and even if we hit 30 cents it wouldn't take much to double. gl


Oh I'm here Woundedknee.

I'm taking shares from the scared - buying more at lower prices.  I really don't want to buy anymore but I can't say "NO" to a good deal.  Hahaha!

There are a few reasons I'm excited ...
1.  Phase 3 (prep, start, dose setting decision)
2.  NASDAQ ... to go hand-in-hand with Phase 3 exitement
3.  Partnership deals for OTENA
4.  New drug development - assuming our next drug will be a Rivastigmine concoction for AD

I found Biogen's $18B jump in share price to be encouraging ... not because they have a winner for AD (far, far from it) ... but ... because the world is looking for some hope and I think we can do much better in terms of drug potential).

Personally, I don't care about Dan's tax planning - small in relation to what ATE is all about.  I fully expected some financial jockying to occur with his share windfall.  I'm just glad he dealt with it now rather than when we get some momentum going with the share price (IMO).

And "YES" to your point about the share price being able to double easily ... under the right conditions ... I fully expect we'll have our moment in the sun.  Just gotta wait for the clouds to move.  Best way for me to kill time while I wait ... fishing for some cheap shares.

All in my opinion.

: )
<< Previous
Bullboard Posts
Next >>